Could a tiny needle zap away shoulder pain? new trial tests best frequency

NCT ID NCT07269925

Recruiting now Symptom relief Sponsor: Universidad Complutense de Madrid Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares two electrical frequencies (high vs. low) used in percutaneous electrical nerve stimulation (PENS) for shoulder pain. Thirty adults with a trigger point in the infraspinatus muscle will receive a single session, and researchers will measure changes in muscle strength and pain sensitivity. The goal is to find the optimal dosage for this technique, which is still being explored for chronic pain.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Percutaneous electrical nerve stimulation (PENS) at high or low frequency
What this could lead to: If successful, this could help identify the best electrical frequency for easing shoulder pain and improving muscle strength using a needle-based stimulation technique.
What could go wrong: This is a small, early-phase study with only 30 participants and no control group, so results may not apply broadly. The technique is still experimental and its benefits over standard treatments are not proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYOFASCIAL TRIGGER POINT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myofascial pain syndrome Shoulder Pain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SHOULDER PAIN

Contacts and locations

Locations

ATMIS
NOT_YET_RECRUITING

Krakow, Poland, Poland
ATMIS
RECRUITING

Nowy Targ, 34-400, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.